Feasibility and potential benefits of preoperative chemotherapy with Gemcitabine+nab/Paclitaxel in patients with resectable pancreatic cancer: a multicenter phase I/II trial (APCS-01 study).
- Conditions
- resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000033901
- Lead Sponsor
- Hirosaki University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Not provided
1. Patient with the treatment history of gemcitabine or nab/paclitaxel. 2. R0 resection is judged to be impossible. 3. Patient with sever diarrhea. 4. Patient with sever ascites and pleural effusion. 5. Patient with active other cancer. 6. Patient with sever coexisting disease. 7. Patients with active infectious disease. 8. Patient with remarkable abnormal electrocardiogram or sever cardiac disorder. 9. Patient with severe psychiatric disorder. 10. Pregnant female, lactating female, female who might be pregnant, female who hopes to be pregnant, and male who hopes the partner's pregnancy. 11. Patient with the history of sever medication allergy. 12. Patient with continuous systemic administration of the steroid. 13. Patient with contraindication of gemcitabine and nab-paclitaxel. 14. Patient where the attending doctor judged unsuitable for safely carrying out.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method relapse-free survival time
- Secondary Outcome Measures
Name Time Method completion rate of preoperative chemotherapy, over-all survival time, down-staging rate, R0 resection rate, adverse event rate, anti-tumor efficacy